These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19337197)

  • 21. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted CML therapy: controlling drug resistance, seeking cure.
    O'Hare T; Corbin AS; Druker BJ
    Curr Opin Genet Dev; 2006 Feb; 16(1):92-9. PubMed ID: 16343892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
    Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
    J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
    Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
    J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
    Jabbour E; Kantarjian H; Cortes J
    Semin Hematol; 2010 Oct; 47(4):344-53. PubMed ID: 20875551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.
    Bumbea H; Vladareanu AM; Voican I; Cisleanu D; Barsan L; Onisai M
    J Med Life; 2010; 3(2):162-6. PubMed ID: 20968202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ever-advancing chronic myeloid leukemia treatment.
    Kimura S; Ando T; Kojima K
    Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies in controlling drug resistance.
    Frame D
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
    Zeidan A; Wang ES; Wetzler M
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):673-83. PubMed ID: 18827790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
    Kujawski L; Talpaz M
    Leuk Lymphoma; 2007 Dec; 48(12):2310-22. PubMed ID: 18067005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
    Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
    J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
    Breccia M
    Nat Rev Clin Oncol; 2010 Oct; 7(10):557-8. PubMed ID: 20877419
    [No Abstract]   [Full Text] [Related]  

  • 39. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
    Cornelison AM; Kantarjian H; Cortes J; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.